Clinical trials
Phase 1/2 Leiomyosarcoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Recruiting | 4 |
| Terminated | 3 |
| Unknown status | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Grupo Espanol de Investigacion en Sarcomas | 2 |
| Broto, Javier Martín, M.D. | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| N.N. Petrov National Medical Research Center of Oncology | 1 |
| National Taiwan University Hospital | 1 |
| OncoResponse, Inc. | 1 |
| STORM Therapeutics LTD | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leiomyosarcoma | 15 |
| Liposarcoma | 12 |
| Sarcoma | 11 |
| Histiocytoma, Malignant Fibrous | 7 |
| Neurofibrosarcoma | 7 |
| Sarcoma, Synovial | 7 |
| Chondrosarcoma | 5 |
| Fibrosarcoma | 4 |
| Hemangiosarcoma | 4 |
| Osteosarcoma | 4 |
Trials
Showing 26 to 15 of 15. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.